Cullinan Therapeutics Inc. (CGEM)
CGEM trades on Nasdaq in Health Care, Biotechnology: Biological Products (No Diagnostic Substances). Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price · October 14, 2026
$14.10
-5.69% on the day
Market cap
$907.4M
Small cap
Revenue
No annual revenue filed since the period ending 2022-12-31
Net income
No annual revenue filed since the period ending 2022-12-31
Price, change, market cap, sector and industry: Nasdaq stock screener, as of October 14, 2026.
Profile
| Field | Value |
|---|---|
| Ticker | CGEM on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) |
| Country | United States |
| IPO year | 2021 |
| SEC CIK | 0001789972 |
| SEC industry code | Biological Products, (No Diagnostic Substances) |
| Incorporated in | DE |
Financials
No annual revenue filed since the period ending 2022-12-31.
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | S-3ASR | 2026-04-28 |
| Latest annual report | 10-K | 2026-03-10 |
| Latest quarterly / interim | 10-Q | 2026-08-06 |
| Latest current report | 8-K | 2026-10-02 |
| Latest proxy | DEFA14A | 2026-04-28 |
Source: SEC EDGAR submissions feed, 464 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | -12.5% |
| 1 month | -33.4% |
| 3 months | -16.6% |
| Year to date | +32.2% |
| 1 year | +74.7% |
| From 52-week high | -40.4% |
Source: Yahoo Finance daily closes, last bar 2026-10-14. Computed by Sophia Capital from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Biological Products (No Diagnostic Substances)
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| MGTX | MeiraGTx Holdings plc | $9.94 | -4.24% | $954.7M |
| SLBT | SL Science Holding Limited | $1.53 | +1.32% | $858.0M |
| GLUE | Monte Rosa Therapeutics Inc. | $9.89 | -5.99% | $843.7M |
| ODTX | Odyssey Therapeutics Inc. | $17.24 | -5.59% | $828.5M |
| IMTX | Immatics N.V. | $6.83 | -5.27% | $1.0B |
| DNA | Ginkgo Bioworks Holdings Inc. | $11.76 | -0.25% | $756.6M |
| VOR | Vor Biopharma Inc. | $19.06 | -3.74% | $1.1B |
| REPL | Replimune Group Inc. | $12.11 | -7.34% | $1.1B |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier